GlassScriptPhysician profile
Calvin Adatsi
NPI 1033767082
$881.24
in general payments reported to CMS, 2019-2025
13 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $180 · 2023: $299 · 2024: $82.87 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $239.58 | 2022-2025 | Farxiga, Wainua, Brilinta |
| Janssen Pharmaceuticals, INC | $121.05 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.34 | 2022-2025 | Lifevest |
| Pfizer INC. | $96.62 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $76.43 | 2023-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $46.13 | 2022-2023 | |
| Zoll Circulation INC | $35.32 | 2021 | |
| Elutia, INC. | $33.49 | 2022 | |
| Medtronic, INC. | $32.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.07 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.24 | 2023 | Jardiance |
| Edwards Lifesciences Corporation | $20.06 | 2024 | Mitris Resilia Mitral Valve |
| United Therapeutics Corporation | $17.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Adatsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.